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PRENATAL OPIOID MAINTENANCE IN THE U.S. AND ITS EFFECT ON NEONATAL
ABSTINENCE SYNDROME: THE CASE OF WEST VIRGINIA’S OPIOID EPIDEMIC

ABSTRACT
In 2017, West Virginia’s opioid epidemic was the cause of about 1000 deaths. Opioid abuse has
become an issue among pregnant mothers and has increased the effects of Neonatal Abstinence
Syndrome (NAS) in infants. The purpose of this study was to evaluate the participation of prenatal
opioid maintenance to determine if it has decreased the amount of treatment needed for NAS in infants
in West Virginia. The methodology utilized a literature review complemented with a semi-structured
interview. Thirty-six sources were referenced for this literature review. It was found that
Buprenorphine Maintenance Therapy had the most positive effect on NAS after birth. This review also
reported a lack of availability for addicted pregnant women to enroll in maintenance programs and a
high drop-out rate. Opioid maintenance therapy has permitted pregnant women to refrain from illicit
drug use without experiencing withdrawal symptoms and it has allowed the opportunity for their infants
to have better health after birth.
Key Words: Infants, Maintenance, NAS, Opioid, Pregnant, and West Virginia.

1

INTRODUCTION
The opioid epidemic in the United States (US) has led to 42,249 overdose deaths per year, and in West
Virginia it was the cause of 52 per 100,000 deaths.1 In 2017, more than 115 Americans died per day
from opioid overdose: the CDC estimated a total of $78.5 billion per year has been consumed on
healthcare due to loss of productivity, addiction treatment, and criminal justice related to opioid abuse.2
Excessive opioid abuse in the US has increased the occurrence of Neonatal Abstinence Syndrome
(NAS) among infants, especially in West Virginia.3
NAS occurs in infants who have been exposed to opioid usage by drug dependent mothers
throughout pregnancy.4 NAS has been defined as an opioid withdrawal syndrome that has been found in
55% to 94% of newborns whose mothers have used opioid drugs while pregnant.5 It has been caused by
the use of Heroin, Codeine, Oxycodone, Methadone, and Buprenorphine, which has led to health
complications that have commenced within one to three days after birth.6 The WEST VIRGINIA state
average of children born with NAS was 7.74 per 1,000 births in 2007 and increased to 31.56 per 1,000
births by 2013, which was three times the national average.7
Prenatal drug rehabilitation centers have used Methadone Maintenance Therapy (MMT) and
Buprenorphine Maintenance Therapy (BMT) and has sustained opioid maintenance in addicted pregnant
mothers.8 The Maternal Addiction Recovery Center (MARC) Program in Huntington, West Virginia at
Marshall Obstetrics & Gynecology has offered the combination of prenatal care and medication
maintenance to opioid-addicted pregnant women.9 Buprenorphine and Methadone have worked as
opioid agonists and have contained chemicals that have linked to the brain’s opioid receptors and have
reduced withdrawal symptoms from Heroine or other opioids, managed pain, and have created a sense
of well-being.10 MMT and BMT during pregnancy has stabilized the amount of opioids within the fetus,
decreased the risk of transmitting HIV to the fetus, and has improved overall neonatal health.11 The use
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of Suboxone has also been implemented during pregnancy, which has consisted of the combination of
Buprenorphine and Naloxone. 12 Researchers conducted the Maternal Opioid Treatment: Human
Experimental Research (MOTHER) project, which compared Buprenorphine and Methadone treatment
among opioid addicted pregnant women, and concluded that Buprenorphine has been the most effective
form of treatment for prenatal opioid dependence.13
The purpose of this research study was to evaluate the participation of prenatal opioid
maintenance to determine if it has decreased the amount of treatment needed for Neonatal Abstinence
Syndrome in infants in West Virginia.
METHODOLOGY
The primary hypothesis for this study was that opioid maintenance therapy among pregnant women has
decreased the occurrence and severity of NAS in infants. The methodology for this research analysis
utilized a literature review of academic sources. The conceptual framework, illustrated by Figure 1,
showed an adaptation of the research framework by Brogly, Hahn, Diaz, & Werler14, which
demonstrated the benefits and barriers to opioid maintenance treatment during pregnancy. The use of
this framework was appropriate because it demonstrated the adoption of MMT and BMT within prenatal
drug treatment programs. It was similar to any project development in that the process was circular; it
began with identification and definition of the opioid crisis and included development solutions. In this
case, the solution has been preventing illicit drug usage or withdrawal during pregnancy through the use
of maintenance medications to reduce NAS severity. Through process assessment, the use of opioid
maintenance among pregnant women was researched, and the statistics showed positive effects on the
infants after birth. Once prenatal drug treatment programs implemented the usage of medicatedmaintenance therapy, benefits and barriers were addressed (Figure 1).
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The literature review was conducted in three individual stages involving: (1) developing a search
strategy and gathering data for the case study; (2) determining and analyzing the relevant literature; (3)
delegating literature to appropriate categories.

Step 1: Literature Identification and Collection
The electronic databases used include JAMIA, Elibrary, PubMed, Medline, and Google Scholar.
The terms searched within each database were: “prenatal drug programs” AND “opioid maintenance”
OR “opioid therapy” AND “Neonatal Abstinence Syndrome” OR “NAS” OR “neonatal withdrawal
syndrome” AND “West Virginia” OR “US”. Journals cited included: The Journal of the Medical
Library Association, West Virginia Medical Journal, The Journal of Rural Health, Journal of Addiction
Research & Therapy, and other reliable medical and government websites. The searched identified 117
applicable citations and articles were excluded (N=81) if they did not meet inclusion principles. Articles
were included (N=36) if they described prenatal opioid maintenance treatment protocol or the opioid
epidemic in the US and West Virginia. These 36 articles were subject to full-text review and all 36 were
included in the data abstraction and analysis (Figure 2).

Step 2: Literature Analysis
As the US and WEST VIRGINIA opioid crisis has continued to rise, it has become important to
know its impact on pregnant women and their infants. Therefore, the literature analyzed focused on the
following key areas: the utilization MMT and BMT, opioid maintenance completion, and severity of
NAS after treatment has been administered. In attempt to collect the most recent data, sources preceding
years 2008-2018 were removed from the search and only sources written in English were used. Primary
and secondary data from articles, literature reviews, research studies, and reports written in the US were
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included in this research. The literature review included 36 references which were assessed for
information pertaining to this research project. Furthermore, a semi-structured interview with an expert
Nurse Coordinator of prenatal opioid maintenance, (N.Lindsey) supplemented information to the data
collected (See Appendix A: Questions Asked in Semi-Structured Interview of an Expert in Prenatal
Opioid Maintenance). The Nurse Coordinator will be referred to as Expert in Prenatal Opioid
Maintenance throughout the review. The interview was tape recorded with IRB approval prior to
execution, and only relevant answers were used to supplement the information found in this literature
review. The literature search was conducted by MR and validated by AC, who acted as second reader
and also double checked if references met the research study inclusion criteria.

Step 3: Literature Categorization
The following subheadings were included in part of the following research framework: Illicit
Opioid Use During Pregnancy in the US and West Virginia, Infants with NAS in the US and West
Virginia, MMT and BMT During Pregnancy, and Prenatal Opioid Maintenance Programs.

RESULTS
Illicit Opioid Use During Pregnancy in the US and West Virginia
From 2008-2012, approximately 39.4% of female Medicaid patients and 27.7% of privately
insured patients that were of childbearing age (15-44 years old) received opioid prescriptions each
year.15 These researchers also stated that out of more than 1 million Medicaid patients, 21.6% of
pregnant women filled an opioid prescription and 2.5% of prescriptions exceeded 30 days. In 2011, 5%
of women ages 15-44 years old in the US used illicit drugs while pregnant.16 In addition, 138,224 out of
55,781,965 hospitalizations among pregnant women were due to opioid abuse. More than 35% of
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opioid dependent women have also tested positive for marijuana, cocaine, benzodiazepines, and 77%95% and have smoked tobacco.17
A study conducted in 2009 reported that 146 out of 759 pregnant women in WEST VIRGINIA,
or 19.2% tested positive for drug or alcohol abuse.18 In 2010, 1 out of 3 pregnant women positively
tested for opioid abuse at Charleston Area Medical Center’s (CAMC) Women’s Medicine Center in
Charleston, West Virginia, but increased to 37% percent during the first quarter of 2011. Furthermore,
CAMC tested 706 pregnant mothers between July 2010 and July 2011, which showed usage of 74%
marijuana, 20% opioid, 12% Benzodiazepines, and 6% Methadone.19

Infants with NAS in the US and West Virginia
Infants that have been born with NAS in the US more than doubled between years 2009 and
2013, with an increased rate of 3.6 per 1,000 infants to a rate of 7.3 per 1,000.20 One study stated that in
2012, US hospitals expended $316 million on infants with NAS, whose average length of stay was 16.6
days, or 3.5 times more than a non-NAS infant.21 Drug dependent infants in the US have had a 150%
greater chance of being readmitted into the hospital within 30 days after birth than infants born without
any health complications.22 Medicated-maintenance has been utilized to treat withdrawal symptoms in
50%-70% of infants born with NAS.17
In 2016, the frequency of NAS among infants In West Virginia was approximately 5% of total
births.23 This author also stated an increase from the two previous years, with 32.1% of infants born
with NAS in 2014 and 34.4% in 2015. Another report in 2017 suggested that newborns with NAS were
born every 25 minutes in West Virginia.24 In 2013, 18% of infants in Huntington, West Virginia, were
born with NAS, compared to the statewide rate of 37% and the nationwide rate of 7%.25 Four years later
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at Cabell Huntington Hospital in Huntington, West Virginia, 14% of infants were born with NAS,
compared to the national average of 6% newborns.26
According to West Virginia perinatal collaborative officials, 33.3% of infants with NAS have
been treated in well newborn nurseries, while the remaining 66.7% have been treated special care
nurseries or the Neonatal Intensive Care Unit (NICU). Furthermore, drug dependent infants have cost
an average daily charge of $400 in West Virginia’s neonatal withdrawal centers, $2,600 in a special care
nursery, and $4,000 in a NICU.27 A study conducted by West Virginia University suggested that the
average length of stay for newborns with NAS was 18 days, which resulted in an overall hospitalization
cost of $9,000-$12,600.28 Lily’s Place, an extended NAS treatment facility in Huntington, West
Virginia, has kept infants for 2 weeks to 12 months for addiction withdrawal treatment but only has 12
available beds: they have treated 91 infants since opening in 2014.25

Methadone and Buprenorphine Maintenance Therapy During Pregnancy
According to the MOTHER project, infants whose mothers participated in MMT during
pregnancy had a hospital stay extent of 15-20 days and NAS treatment duration of 10 days, whereas
infants whose mothers used BMT had a hospital stay of 10 days and NAS treatment duration for less
than 5 days.29 Researchers have suggested that within 4 weeks of the being transitioned from MMT to
BMT, 15% of women showed illegal drug usage in urine screening, 90% continued follow-up
appointments until delivery of the child, and 38.9% did not use drugs illicitly at the time of delivery.30
Furthermore, there were fewer cases of NAS and shorter hospitals stays after birth when transitioned
from MMT to BMT.
A recent study showed that BMT, rather than single-methadone treatments, has shown a 10%
lower chance of NAS, 8.4 fewer days of neonatal treatment, and 3.6 mg less Morphine treatment.31
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BMT has shown a longer duration of movements and less suppression in motor activity in infants.32
Researchers from West Virginia University reported that 81% of infants who have been exposed to
MMT still needed treatment for NAS, while only 26% who were exposed to BMT required NAS
treatment.33 In a study that involved 716 women participating in MMT or BMT, infants whose mothers
were exposed to MMT showed a 65% incidence of NAS, whereas those exposed to BMT showed
49%.34 This study also showed 17 more cases of NAS when mothers participated in MMT rather than
BMT.

Prenatal Opioid Maintenance Programs
The MARC Program in Huntington, West Virginia has the capacity to treat 36 patients, which
have ranged from ages 22-34 years of age.35 However, upon the occasion that MARC has been unable
to treat anymore patients, they have contacted an alternate facility and placed them on their waiting list.
The Expert in Prenatal Opioid Maintenance stated that drug tests, which have included urine and blood
screenings, have been performed weekly. Furthermore, if drugs screenings were not clear, a breach in
contract has occurred, and patients must discontinue treatment. The Expert reported that Buprenorphine
has been administered to MARC patients during the term of pregnancy at a maximum dose of 16 mg per
day. After delivery, however, patients have been prescribed Suboxone, which also has a maximum dose
of 16 mg per day. Each patient has been prescribed a different dose depending on each individual’s
level of addiction and have experienced minimal side effects such as nausea or headaches.35 In addition
to medication, the Expert also stated that patients have been required to attend group counseling,
monthly individual meetings, and two Narcotics Anonymous meetings per month. The Expert reported
that there have not been any cases of overdose while participating in the MARC Program.
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One study in 2017 stated that only 16% of drug dependent pregnant women have successfully
completed an opioid maintenance program and sustained from illicit drug use until the time of
delivery.36 Researchers have found that the dropout rate of mothers who used Buprenorphine as
maintenance medication was 33%, which was significantly higher than the 18% dropout rate of pregnant
women who used Methadone during maintenance therapy.36 Between the years of 1992-2012, the
number of pregnant women who were admitted into prenatal opioid therapy facilities due to prescription
opioid drug usage increased from 2% to 28%.15 Finally, a study that consisted of 95 women showed that
44% relapsed and resorted to illicit drug use before giving birth.17

DISCUSSION
The purpose of this research study was to evaluate the participation of prenatal opioid maintenance to
determine if it has decreased the amount of treatment needed for Neonatal Abstinence Syndrome in
infants. The primary hypothesis for this study was that opioid maintenance therapy among pregnant
women has decreased the occurrence and severity of NAS in infants. This analysis showed that prenatal
opioid maintenance, especially with the use of Buprenorphine, has decreased the need for NAS
treatment after birth and increased overall health in infants born to mothers who have participated in
medication maintenance therapy.
One study showed that 5% of women within child bearing ages illicitly used opioids during their
term of pregnancy.16 In West Virginia, the amount of opioid-addicted pregnant women has continued to
increase each year: this has resulted in more than twice as many cases of NAS. Hospitals have
expended over $300 million to treat infants with NAS, which have required 3.5 longer hospital stays
than healthy newborns due to medicated-maintenance and health complications.21 Holdren23 suggested
that NAS occurred in 5% of total births in West Virginia in 2016, which has shown a continual increase
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each year. Cabell Huntington Hospital in Huntington, West Virginia, had 8% more cases of NAS than
the remainder of hospitals in the state.
Studies have shown that BMT throughout pregnancy has been more effective for NAS after
delivery than MMT. Johnson & Martin30 reported less cases of NAS and a shorter length of stay with
BMT. Furthermore, another study found that a significant amount of MMT exposed infants still needed
treatment, compared to those who were exposed to BMT.34 The MARC Program in Huntington, West
Virginia has had a 100% completion rate using BMT, with minimal side effects. After delivery, MARC
patients have been prescribed Suboxone for maintenance. Patients have also attended counseling and
meetings as supplementary forms of treatment (Expert in Prenatal Opioid Maintenance, 2018). On the
contrary, Klaman, et. al.35 reported only 16% of women have completed a program without returning to
illicit drug use. Furthermore, the need for prenatal opioid maintenance has continued to increase.
Between 1992-2012, the need for medication maintenance increased by 26%.15
A positive component of opioid maintenance therapy throughout the term of pregnancy in West
Virginia and the US has been the decrease in necessary treatment and severity of NAS in infants after
birth. BMT has decreased the occurrence of NAS in infants to 49% and has decreased treatment needed
for those born with NAS.
A negative component to prenatal opioid maintenance has been the dropout or relapse rate of
pregnant mothers. Prenatal opioid maintenance programs also have not had the capacity to treat every
opioid-addicted pregnant mother that has been seeking medication maintenance therapy.

Limitations and Practical Implications
This research study was not conducted without its limitations. Prenatal opioid maintenance programs
have not had the capacity for all pregnant mothers who have needed treatment, which has resulted in
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NAS severity among infants. This literature review was restricted due to search strategy such as
difficulty distinguishing generic drug names, number of databases or sources found, which may have
affected the availability or accuracy of the research, and finally research and publication bias. Further
research of Buprenorphine, Methadone, or new drugs is needed to ensure better results of NAS
occurrence in the future. Continual participation in maintenance medication and cooperation of opioidaddicted pregnant women will help with further research regarding the occurrence and severity of NAS
in newborns. BMT has decreased the need for opioid treatment in infants after birth and improved their
overall health. The practical implications of prenatal opioid maintenance outcomes will need to be more
heavily researched as more pregnant mothers continue to participate or drop-out of programs and new
drugs come into the market.

CONCLUSION
Participation in opioid maintenance therapy during pregnancy has shown a decrease in severity of NAS
infants. This literature review has suggested that BMT has been the most effective form of treatment
thus far.
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Figure 1: Conceptual Research Framework
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2. Overview of citation evaluation.
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APPENDIX A
Questions Asked in Semi-Structured Interview of an Expert in Prenatal Opioid Maintenance on
March 20, 2018
•

What is your rate of relapse?

•

How often have patients become opioid-free by the time of delivery? Why?

•

How frequently do you perform drug tests?

•

What is the range of ages currently enrolled? Why?

•

Does a certain age group have a higher completion rate? Why?

•

How many women can you have enrolled at once?

•

How many women do you have to turn away? Why?

•

What are the requirements/repercussions of staying in the program?

•

What maintenance medication do you use? Why?

•

How often is medication administered? Why?

•

If more than one form of treatment is used, have you found one to be more effective than
the other? Why?

•

What are the side effects of medication used for treatment?

•

How many miscarriages have been reported?

•

Have any women overdosed while participating in your program?
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•

If known, how has your program impacted the infants of your patients? Why?
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